Hengrui Pharma(SH:600276) 天天基金网·2025-09-05 05:11Core Viewpoint - Heng Rui Medicine has signed a licensing agreement with Braveheart Bio for the innovative drug HRS-1893, which could yield milestone payments up to $1.013 billion [5][8]. Group 1: Licensing Agreement Details - The agreement allows Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding Greater China [7]. - HRS-1893 is a Myosin selective inhibitor currently in Phase III clinical development for treating obstructive hypertrophic cardiomyopathy (oHCM) [7]. - Braveheart Bio will pay an upfront fee of $65 million, including $32.5 million in cash and $32.5 million in equity, plus an additional $10 million upon technology transfer completion [8]. Group 2: Financial Implications - Heng Rui Medicine is eligible for milestone payments related to clinical development and sales, potentially reaching $1.013 billion [5][8]. - The agreement is expected to enhance Heng Rui's international market presence and improve its innovative brand and overseas performance [8]. Group 3: Recent Developments - Heng Rui Medicine has initiated its first A-share buyback, purchasing 270,000 shares at a total cost of approximately 18.31 million yuan [11]. - The company reported a revenue of 15.761 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, with a net profit of 4.450 billion yuan, up 29.67% [12].